Available Until 4/26/2024

Expanding the Impact of Antimicrobial Stewardship (Act Local)


A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) and the Center for Infectious Disease Research and Policy (CIDRAP) 

 View more SIDPEC Activities

Activity Description

Join CIDRAP-ASP for a webinar reviewing the importance of data generated by diagnostic laboratories, and how these data can be efficiently connected with clinical outcomes and used in infection prevention strategies to prevent or disrupt outbreaks.

Target Audience

This program has been designed to meet the educational needs of physicians, pharmacists, and laboratory professionals.

Learning Objectives

At the completion of this activity, the participant will be better able to:

  • Describe what data are generated and reported from diagnostic laboratories in healthcare systems.
  • Explain how to connect diagnostic data with clinical outcomes.
  • Implement appropriate infection prevention strategies based on antimicrobial and diagnostic stewardship data.


Moderator: Marnie Peterson, PharmD, PhD, Outreach Coordinator, CIDRAP

Elizabeth Monsees, PhD, MBA, RN, CIC, FAPIC
Antibiotic Stewardship Program Manager, Children’s Mercy Kansas City

Bradley Langford, BSc, BScPhm, ACPR, PharmD, BCIDP, MPH(c)
Antimicrobial Stewardship Pharmacist, Public Health Ontario, Hotel Dieu Shaver Hospital

CME/CE Accreditation

Release Date: April 26, 2022
Expiration Date: April 26, 2023

ACPE Credit Designation (Pharmacist CE)

This activity is jointly provided by ProCE, LLC, CIDRAP (Center for Infectious Disease Research and Policy), and SIDP (Society of Infectious Diseases Pharmacists). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-22-084-H01-P has been assigned to this home study knowledge-based activity. This CE activity is approved for 1.25 contact hours (0.125 CEU) in states that recognize ACPE providers. This CE activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by ProCE, LLC and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Clinical Laboratory Professionals CE

The Clinical and Laboratory Standards Institute is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.


The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certified infectious diseases pharmacist (BCIDP) credit. A BCIDP statement of credit will be issued online upon successful completion of a post-test and online evaluation. The post-test must be successfully completed in only one attempt. No partial credit will be given. BCIDP accreditation begins 4/26/2022 for this activity and is available for one year from this date.

Recertification Criteria for Infectious Diseases Pharmacy: BCIDP recertifying via continuing education are required to earn 100 hours of continuing education credit provided by the joint program offered by the Society of Infectious Diseases Pharmacists (SIDP), the American College of Clinical Pharmacy (ACCP) and the American Society of Health-System Pharmacists (ASHP). Infectious Diseases Pharmacy Specialty Recertification Courses offered by any of the approved providers may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle. Candidates should note that there are expiration dates associated with earning BPS recertification credit. BPS will only award recertification credit for modules based on the completion and submission date of the post-test assessment. For example, a module completed and submitted on October 20 of a particular year will only be credited for that year, even if the due date of the post-test is in January of the following year. View all recertification criteria on the BPS website at https://www.bpsweb.org/recertification/recertification-by-continuing-education


ProCE, LLC and Clinical Care Options, LLC (CCO) require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE and CCO policy. ProCE and CCO are committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Marnie Peterson, PharmD, PhD reports having co-ownership of Perfectus Biomed.
Bradley J. Langford, PharmD, BCIDP, MPH(c) has no relevant conflicts of interest to report.
Elizabeth Monsees, PhD, MBA, RN, CIC, FAPIC has no relevant conflicts of interest to report.
Kristine Moore, MD, MPH has no relevant conflicts of interest to report.
Maya Peters, MPH has no relevant conflicts of interest to report.
CCO and ProCE Staff have no relevant conflicts of interest to report.

Potential conflicts of interest were resolved with a peer review process provided by Kristine Moore, MD, MPH.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


This CE activity is supported by an educational grant from BioMérieux.

The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.